| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/16/2023 | 162.01% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 06/14/2021 | 162.01% | HC Wainwright & Co. | $4 → $6 | Maintains | Buy |
| 08/05/2020 | 74.67% | HC Wainwright & Co. | → $4 | Initiates Coverage On | → Buy |
What is the target price for Phio Pharma (PHIO)?
The latest price target for Phio Pharma (NASDAQ: PHIO) was reported by HC Wainwright & Co. on August 16, 2023. The analyst firm set a price target for $6.00 expecting PHIO to rise to within 12 months (a possible 162.01% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Phio Pharma (PHIO)?
The latest analyst rating for Phio Pharma (NASDAQ: PHIO) was provided by HC Wainwright & Co., and Phio Pharma reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Phio Pharma (PHIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Phio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Phio Pharma was filed on August 16, 2023 so you should expect the next rating to be made available sometime around August 16, 2024.
Is the Analyst Rating Phio Pharma (PHIO) correct?
While ratings are subjective and will change, the latest Phio Pharma (PHIO) rating was a reiterated with a price target of $0.00 to $6.00. The current price Phio Pharma (PHIO) is trading at is $2.29, which is within the analyst's predicted range.